```
=> s (micelle# or pro-micelle# or pro(a)micelle#)
L1        92603 (MICELLE# OR PRO-MICELLE# OR PRO(A) MICELLE#)

=> s (microemulsion# or micro(a)emulsion#)
L2        26544 (MICROEMULSION# OR MICRO(A) EMULSION#)

=> s (liposome#)
L3       158907 (LIPOSOME#)

=> s (C12 or C13 or C14 or C15 or C16 or C17 or C18 (5a)ester?)
L4       132162 (C12 OR C13 OR C14 OR C15 OR C16 OR C17 OR C18 (5A) ESTER?)

=> s l4 and (l1 or l2 or l3)
L5         4992 L4 AND (L1 OR L2 OR L3)

=> s l5 and (phospholipid# or surfactant# or detergent#)
L6         3698 L5 AND (PHOSPHOLIPID# OR SURFACTANT# OR DETERGENT#)

=> s l6 and (insulin#)
L7          508 L6 AND (INSULIN#)

=> s l7 and (gelatin#)
L8          365 L7 AND (GELATIN#)

=> s l8 and (coconut#)
L9           28 L8 AND (COCONUT#)

=> s Cho, Y?/au
L10       10933 CHO, Y?/AU

=> s l9 and l10
L11           3 L9 AND L10

=> d l11 1-3 bib ab

L11  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1995:716960  CAPLUS
DN   123:93291
TI   Microparticular pharmaceutical compositions in micellar form
IN   Cho, Young W.
PA   Isotech Medical, Inc., USA
SO   PCT Int. Appl., 66 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 9512385          A1   19950511       WO 1994-US12351  19941103
         W:  CA, JP, KR, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     CA 2175494          AA   19950511       CA 1994-2175494  19941103
     EP 726761           A1   19960821       EP 1995-901066   19941103
     EP 726761           B1   20010110
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     AT 198547           E    20010115       AT 1995-901066   19941103
     ES 2155512          T3   20010516       ES 1995-901066   19941103
     US 5858398          A    19990112       US 1996-635945   19960502
     HK 1014150          A1   20010921       HK 1998-114523   19981221
PRAI US 1993-146747      A    19931103
     WO 1994-US12351     W    19941103
AB   A pharmaceutical compn. comprises microparticles in micelles.
     The microparticles contain at least one of each a pharmaceutically-active
```

agent, a water or lipid-sol. or -miscible **phospholipid**, a nonionic **surfactant** having an HLB value of .gtoreq. 15 and .ltoreq. 6, and a water-sol. or -miscible sterol compd. The compn. is prepd. by admixing the components, micronizing the admixt. to form microparticles, and suspending the microparticles in at least one fatty acid of chain length of **C14** or less to form microparticles in **micelles**. The invention may be useful in the oral administration of drugs and other therapeutic agents, as well as for the trans-umbilico-dermal administration of such drugs and therapeutic agents. Oral **insulin** formulations with enhanced bioavailability and activity were prepd.

L11 ANSWER 2 OF 3 USPATFULL on STN
AN 2003:113453 USPATFULL
TI **Pro-micelle** pharmaceutical compositions
IN **Cho, Young W.**, Fremont, CA, UNITED STATES
Lee, Kwang-Ho, Fremont, CA, UNITED STATES
PI US 2003078194 A1 20030424
AI US 2001-974942 A1 20011011 (9)
DT Utility
FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides **pro-micelle** compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C.sub.12-C.sub.18 fatty acids. In the mammalian intestine, exposure to C.sub.12-C.sub.18 fatty acids results in conversion of the **pro-micelle** to a stable **micelle** that effectively delivers the pharmaceutically active agent to the systemic circulation. The present invention further provides methods of making and using such compositions.

L11 ANSWER 3 OF 3 USPATFULL on STN
AN 1999:4069 USPATFULL
TI Microparticular pharmaceutical compositions
IN **Cho, Young W.**, Cincinnati, OH, United States
PA Isomed Inc., Apopka, FL, United States (U.S. corporation)
PI US 5858398 19990112
WO 9512385 19950511
AI US 1996-635945 19960502 (8)
WO 1994-US12351 19941103
19960502 PCT 371 date
19960502 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Baker & Botts, L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1760
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition comprises microparticles in **micelle**. The microparticles contain at least one pharmaceutically-active agent, at least one water soluble or miscible **phospholipid**, at least one lipid soluble or miscible **phospholipid**, at least one non-ionic **surfactant** having an HLB value of about 15 or greater, at least one non-ionic **surfactant** having an HLB value of about or less, and at least one water soluble or miscible sterol compound. The microparticles are suspended in at least one fatty acid having a chain length of C.sub.14 or less. The composition may

optionally contain at least one fatty acid having a chain length of C.sub.16 or greater in a concentration of about 5 w/v % or less. The composition is prepared by admixing the pharmaceutically-active agent, **phospholipids**, **surfactants**, and sterol, micronizing the admixture to form microparticles, and suspending the microparticles in at least one fatty acid of chain length of C.sub.14 or less to form microparticles in **micelle**. The invention may be useful in the oral administration of drugs and other therapeutic agents, as well as for the trans-umbilico-dermal administration of such drugs and therapeutic agents.

```
=> s Lee, Kwang-HO/au
L12         153 LEE, KWANG-HO/AU

=> s l9 and l12
L13           1 L9 AND L12

=> d l13 bib ab

L13  ANSWER 1 OF 1  USPATFULL on STN
AN     2003:113453  USPATFULL
TI     Pro-micelle pharmaceutical compositions
IN     Cho, Young W., Fremont, CA, UNITED STATES
         Lee, Kwang-Ho, Fremont, CA, UNITED STATES
PI     US 2003078194      A1   20030424
AI     US 2001-974942     A1   20011011 (9)
DT     Utility
FS     APPLICATION
LREP   BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN   Number of Claims: 18
ECL    Exemplary Claim: 1
DRWN   8 Drawing Page(s)
LN.CNT 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention provides pro-micelle
       compositions comprising a pharmaceutically active agent encapsulated
       with a membrane of esterified C.sub.12-C.sub.18 fatty acids. In the
       mammalian intestine, exposure to C.sub.12-C.sub.18 fatty acids results
       in conversion of the pro-micelle to a stable
       micelle that effectively delivers the pharmaceutically active
       agent to the systemic circulation. The present invention further
       provides methods of making and using such compositions.


=> s l9 and (minicapsule# or mini(a)capsule# or microcapsule# or micro(a)capsule#)
L14          13 L9 AND (MINICAPSULE# OR MINI(A) CAPSULE# OR MICROCAPSULE# OR
                MICRO(A) CAPSULE#)

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15           13 DUP REM L14 (0 DUPLICATES REMOVED)

=> s l15 and (pharmaceut? or therapeut? (5a) composition#)
L16          13 L15 AND (PHARMACEUT? OR THERAPEUT? (5A) COMPOSITION#)

=> dis his

     (FILE 'HOME' ENTERED AT 15:24:57 ON 31 OCT 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 15:25:13 ON 31 OCT 2003
L1         92603 S (MICELLE# OR PRO-MICELLE# OR PRO(A)MICELLE#)
L2         26544 S (MICROEMULSION# OR MICRO(A)EMULSION#)
L3        158907 S (LIPOSOME#)
```

```
L4        132162 S (C12 OR C13 OR C14 OR C15 OR C16 OR C17 OR C18 (5A)ESTER?)
L5          4992 S L4 AND (L1 OR L2 OR L3)
L6          3698 S L5 AND (PHOSPHOLIPID# OR SURFACTANT# OR DETERGENT#)
L7           508 S L6 AND (INSULIN#)
L8           365 S L7 AND (GELATIN#)
L9            28 S L8 AND (COCONUT#)
L10        10933 S CHO, Y?/AU
L11            3 S L9 AND L10
L12          153 S LEE, KWANG-HO/AU
L13            1 S L9 AND L12
L14           13 S L9 AND (MINICAPSULE# OR MINI(A)CAPSULE# OR MICROCAPSULE# OR
L15           13 DUP REM L14 (0 DUPLICATES REMOVED)
L16           13 S L15 AND (PHARMACEUT? OR THERAPEUT? (5A) COMPOSITION#)

=> s l16 and (l9 or l12 or l10)
L17           13 L16 AND (L9 OR L12 OR L10)

=> s l17 and (fatty acid#)
   6 FILES SEARCHED...
L18           13 L17 AND (FATTY ACID#)

=> s l18 and (saturat? or esterif?)
L19           13 L18 AND (SATURAT? OR ESTERIF?)

=> s l19 and (encapsulat? or coat? (5a) film#)
L20           13 L19 AND (ENCAPSULAT? OR COAT? (5A) FILM#)

=> s l20 and (growth hormone#)
L21           11 L20 AND (GROWTH HORMONE#)

=> s l20 and (urokinase#)
L22            7 L20 AND (UROKINASE#)

=> s l20 and (factor VIII or FVIII or factor IX or FIX)
L23           12 L20 AND (FACTOR VIII OR FVIII OR FACTOR IX OR FIX)

=> s l20 and (l21 or l22 or l23)
L24           13 L20 AND (L21 OR L22 OR L23)

=> dis l24 1-13 bib ab

L24  ANSWER 1 OF 13  USPATFULL on STN
AN      2003:257302  USPATFULL
TI      Solid carriers for improved delivery of active ingredients in
        pharmaceutical compositions
IN      Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
        Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI      US 2003180352      A1   20030925
AI      US 2002-159601     A1   20020530 (10)
RLI     Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001,
        PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999,
        GRANTED, Pat. No. US 6248363
DT      Utility
FS      APPLICATION
LREP    REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN    Number of Claims: 55
ECL     Exemplary Claim: 1
DRWN    4 Drawing Page(s)
LN.CNT 4625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention provides solid pharmaceutical
        compositions for improved delivery of a wide variety of active
        ingredients contained therein or separately administered. In one
        embodiment, the solid pharmaceutical composition includes a
        solid carrier, the solid carrier including a substrate and an
```

encapsulation coat on the substrate. The **encapsulation** coat can include different combinations of active ingredients, hydrophilic **surfactant**, lipophilic **surfactants** and triglycerides, and solubilizers. In another embodiment, the solid **pharmaceutical** composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic **surfactants**, lipophilic **surfactants** and triglycerides, and solubilizers. The compositions of the present invention can be used for improved delivery of active ingredients.

L24 ANSWER 2 OF 13 USPATFULL on STN
AN 2003:120747 USPATFULL
TI Blood cell deficiency treatment method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-

androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L24 ANSWER 3 OF 13 USPATFULL on STN
AN 2003:113453 USPATFULL
TI **Pro-micelle pharmaceutical** compositions
IN **Cho, Young W.**, Fremont, CA, UNITED STATES
Lee, Kwang-Ho, Fremont, CA, UNITED STATES
PI US 2003078194 A1 20030424
AI US 2001-974942 A1 20011011 (9)
DT Utility
FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides **pro-micelle** compositions comprising a **pharmaceutically** active agent **encapsulated** with a membrane of **esterified** C.sub.12-C.sub.18 **fatty acids**. In the mammalian intestine, exposure to C.sub.12-C.sub.18 **fatty acids** results in conversion of the **pro-micelle** to a stable **micelle** that effectively delivers the **pharmaceutically** active agent to the systemic circulation. The present invention further provides methods of making and using such compositions.

L24 ANSWER 4 OF 13 USPATFULL on STN
AN 2003:112567 USPATFULL
TI **Pharmaceutical** formulations and systems for improved absorption and multistage release of active agents
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Venkateshwaran, Srinivasan, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Park City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
PI US 2003077297 A1 20030424
AI US 2002-74687 A1 20020211 (10)
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, PENDING Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 145
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to **pharmaceutical** formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have

different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.

L24 ANSWER 5 OF 13 USPATFULL on STN
AN 2003:92739 USPATFULL
TI SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC ACTIVE INGREDIENTS IN **PHARMACEUTICAL** COMPOSITIONS
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI US 2003064097 A1 20030403
US 6569463 B2 20030527
AI US 2001-800593 A1 20010306 (9)
RLI Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 91
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid **pharmaceutical** compositions for improved delivery of a wide variety of **pharmaceutical** active ingredients contained therein or separately administered. In one embodiment, the solid **pharmaceutical** composition includes a solid carrier, the solid carrier including a substrate and an **encapsulation** coat on the substrate. The **encapsulation** coat can include different combinations of **pharmaceutical** active ingredients, hydrophilic **surfactant**, lipophilic **surfactants** and triglycerides. In another embodiment, the solid **pharmaceutical** composition includes a solid carrier, the solid carrier being formed of different combinations of **pharmaceutical** active ingredients, hydrophilic **surfactants**, lipophilic **surfactants** and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic **pharmaceutical** active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

L24 ANSWER 6 OF 13 USPATFULL on STN
AN 2003:13069 USPATFULL
TI Intramuscular delivery of recombinant AAV
IN Clackson, Timothy P., Cambridge, MA, United States
Gilman, Michael, Newton, MA, United States
Holt, Dennis, Royersford, PA, United States
PA Ariad Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6506379 B1 20030114
AI US 2000-481620 20000112 (9)
RLI Continuation-in-part of Ser. No. US 1997-791044, filed on 28 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1995-481941, filed on 7 Jun 1995, now abandoned
PRAI US 1996-15502P 19960209 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Li, Janice
LREP Berstein, David L.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns new configurations for biological switches and provides new methods and materials useful for regulating biological events in animal cells. The invention involves recombinant DNA constructs comprising DNA sequences derived from sequences encoding the proteins FRAP, Tor1, Tor2 and other proteins capable of binding to FKBP:rapamycin, other recombinant DNA constructs comprising DNA sequences encoding part or all of an FKBP protein, the proteins encoded by those constructs, cells (especially animal cells) transformed with one or more of the constructs, small molecules (multivalent multimerizing agents) which bind to and are capable of inducing multimerization of the chimeric proteins, and methods for preparing and using the foregoing, including methods involving the intramuscular delivery of such recombinant DNA constructs in AAV virus particles.

L24 ANSWER 7 OF 13 USPATFULL on STN
AN 2002:199080 USPATFULL
TI Regulation of biological events using novel compounds
IN Clackson, Timothy P., Arlington, MA, UNITED STATES
Gilman, Michael Z., Newton, MA, UNITED STATES
Holt, Dennis A., Schwenksville, PA, UNITED STATES
Keenan, Terence P., Cambridge, MA, UNITED STATES
Rozamus, Leonard, Bedford, MA, UNITED STATES
Yang, Wu, Princeton, NJ, UNITED STATES
PI US 2002107189 A1 20020808
AI US 2001-781804 A1 20010212 (9)
RLI Division of Ser. No. US 1998-12097, filed on 22 Jan 1998, GRANTED, Pat. No. US 6187757 Continuation-in-part of Ser. No. US 1997-791044, filed on 28 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1995-481941, filed on 7 Jun 1995, ABANDONED
PRAI WO 1996-US9948 19960607
US 1996-15502P 19960209 (60)
DT Utility
FS APPLICATION
LREP David L. Berstein, ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

L24 ANSWER 8 OF 13 USPATFULL on STN
AN 2002:8197 USPATFULL
TI Synthetic transcriptional modulators and uses thereof
IN Verdine, Gregory L., Lexington, MA, UNITED STATES
Nyanguile, Origene, Gaithersburg, MD, UNITED STATES
PA President and Fellows of Harvard College (U.S. corporation)
PI US 2002004195 A1 20020110
AI US 2000-751309 A1 20001229 (9)
RLI Continuation of Ser. No. US 1998-208057, filed on 9 Dec 1998, GRANTED, Pat. No. US 6183965 Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997, GRANTED, Pat. No. US 6153383
DT Utility
FS APPLICATION
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 3196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel synthetic transcriptional modulators having at least one selected

ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

L24 ANSWER 9 OF 13 USPATFULL on STN
AN 2001:93131 USPATFULL
TI Solid carriers for improved delivery of active ingredients in **pharmaceutical** compositions
IN Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 6248363 B1 20010619
AI US 1999-447690 19991123 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Reed, Dianne E.Reed & Associates
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 3302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid **pharmaceutical** compositions for improved delivery of a wide variety of **pharmaceutical** active ingredients contained therein or separately administered. In one embodiment, the solid **pharmaceutical** composition includes a solid carrier, the solid carrier including a substrate and an **encapsulation** coat on the substrate. The **encapsulation** coat can include different combinations of **pharmaceutical** active ingredients, hydrophilic **surfactant**, lipophilic **surfactants** and triglycerides. In another embodiment, the solid **pharmaceutical** composition includes a solid carrier, the solid carrier being formed of different combinations of **pharmaceutical** active ingredients, hydrophilic **surfactants**, lipophilic **surfactants** and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic **pharmaceutical** active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

L24 ANSWER 10 OF 13 USPATFULL on STN
AN 2001:22203 USPATFULL
TI Regulation of biological events using novel compounds
IN Clackson, Timothy P., Cambridge, MA, United States
Gilman, Michael Z., Newton, MA, United States
Holt, Dennis A., Royersford, PA, United States
Keenan, Terence P., Cambridge, MA, United States
Rozamus, Leonard, Bedford, MA, United States
Yang, Wu, Plainsboro, NJ, United States
PA ARIAD Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6187757 B1 20010213
AI US 1998-12097 19980122 (9)
RLI Continuation-in-part of Ser. No. US 1997-791044, filed on 28 Jan 1997 Continuation-in-part of Ser. No. US 1995-481941, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. WO 1996-US9948, filed on 7 Jun 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.
LREP Berstein, David L.
CLMN Number of Claims: 54
ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 5678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

L24 ANSWER 11 OF 13 USPATFULL on STN
AN 2001:18213 USPATFULL
TI Synthetic transcriptional modulators and uses thereof
IN Verdine, Gregory L., Lexington, MA, United States
Nyanguile, Origene, Gaithersburg, MD, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 6183965 B1 20010206
AI US 1998-208057 19981209 (9)
RLI Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.
LREP Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 3213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

L24 ANSWER 12 OF 13 USPATFULL on STN
AN 2001:13999 USPATFULL
TI Composite gel microparticles as active principle carriers
IN Lemercier, Alain, St Bonnet de Mure, France
Meyrueix, Remi, Lyons, France
Huille, Sylvain, Lyons, France
Soula, Gerard, Meyzieu, France
PA Flamel Technologies, Venissieux Cedex, France (non-U.S. corporation)
PI US 6180141 B1 20010130
WO 9734584 19970925
AI US 1999-147032 19990104 (9)
WO 1997-FR471 19970314
19990104 PCT 371 date
19990104 PCT 102(e) date
PRAI FR 1996-3546 19960315
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thuaman K.; Assistant Examiner: Benston, Jr., William E.
LREP Dennison, Scheiner, Schultz & Wakeman
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to vectors for delivering medicinal, nutritional, plant-protection or cosmetic active principles, these delivery particles being of small, controllable and adjustable particle size, which protect the active principle, and being biocompatible, biodegradable, non-immunogenic, stable and free of solvent. The particles do not denature the active principle and allow the active principle to be released. The microparticles of the invention are of a cohesive

structure made of a physicochemically stable and integral composite gel which includes an oil such as **coconut** oil, an aqueous phase and a linear, non-crosslinked copolyamino acid of Leu/Glu type (random or diblock). The microparticles have a controllable and adjustable size of between 0.05 and 500 .mu.m.

L24 ANSWER 13 OF 13 USPATFULL on STN
AN 1999:4069 USPATFULL
TI Microparticular **pharmaceutical** compositions
IN **Cho, Young W.**, Cincinnati, OH, United States
PA Isomed Inc., Apopka, FL, United States (U.S. corporation)
PI US 5858398 19990112
WO 9512385 19950511
AI US 1996-635945 19960502 (8)
WO 1994-US12351 19941103
19960502 PCT 371 date
19960502 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Baker & Botts, L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1760
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **pharmaceutical** composition comprises microparticles in **micelle**. The microparticles contain at least one **pharmaceutically**-active agent, at least one water soluble or miscible **phospholipid**, at least one lipid soluble or miscible **phospholipid**, at least one non-ionic **surfactant** having an HLB value of about 15 or greater, at least one non-ionic **surfactant** having an HLB value of about or less, and at least one water soluble or miscible sterol compound. The microparticles are suspended in at least one **fatty acid** having a chain length of C.sub.14 or less. The composition may optionally contain at least one **fatty acid** having a chain length of C.sub.16 or greater in a concentration of about 5 w/v % or less. The composition is prepared by admixing the **pharmaceutically** -active agent, **phospholipids**, **surfactants**, and sterol, micronizing the admixture to form microparticles, and suspending the microparticles in at least one **fatty acid** of chain length of C.sub.14 or less to form microparticles in **micelle**. The invention may be useful in the oral administration of drugs and other therapeutic agents, as well as for the trans-umbilico-dermal administration of such drugs and therapeutic agents.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:03:23 ON 31 OCT 2003